CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytomX Therapeutics reports robust financials and strategic pipeline advancements

CytomX Therapeutics showcased strong financial performance, with a focus on advancing key therapeutic programs and collaborations with industry partners. The company's strategic capital allocation supports pipeline development, while challenges include program prioritization and industry competition. Opportunities for growth exist in advancing pipeline milestones and leveraging collaborations for innovation.

CytomX reports robust Q1 earnings, advances pipeline with key partners

CytomX Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2023
The company's strategic collaborations and focus on innovation position it for future growth
Balancing expenses, regulatory milestones, and clinical progress are key challenges and opportunities
Overall, CytomX is well-positioned to drive value through its transformative therapies

CytomX advances pipeline and partnerships, poised for growth in oncology

CytomX Therapeutics demonstrated strong performance, financial stability, and strategic partnerships in Q2 2023, signaling a promising outlook for future growth.
The company's focus on localized therapies, leadership team strength, and diverse pipeline underscore its competitive position in the biopharmaceutical industry.
While facing challenges in a competitive landscape, CytomX has opportunities for growth through innovative programs, partnerships, and alignment with industry trends.

CytomX Therapeutics reports strong Q3 earnings and outlines strategic roadmap

CytomX Therapeutics showcased solid financial performance in Q3 2023 with revenue of $26.4 million and prudent cost management.
The company's focus on cancer medicines and pipeline advancements position it well for future growth and market competitiveness.
While facing challenges in data updates and cost balancing, strategic milestones and opportunities for collaborations offer avenues for expansion.
Overall, CytomX Therapeutics remains well-positioned in the oncology sector with a strong cash position and promising pipeline candidates.

CytomX posts robust Q4 results, poised for growth in 2024

CytomX Therapeutics delivered a strong performance in Q4 2023, showcasing financial stability, progress on its Probody platform, and strategic partnerships to drive innovation.
While facing challenges in clinical development and partnership dynamics, the company's strengths in product pipeline diversity and financial management offer a solid foundation for future growth.
With exciting opportunities ahead, including upcoming data readouts and advancements in immunotherapy, CytomX is well-positioned to capitalize on its expertise in antibody masking and conditional activation.

CytomX reports positive Phase Ia data for CX-904 therapy

CytomX Therapeutics showcases strong performance with promising drug data.
Company's financial stability and innovative platform position it well for growth.
Challenges in translating research to clinical outcomes and predicting patient responses.
Opportunities lie in expanding drug potential, exploring combination strategies, and addressing assay challenges.

CytomX reports strong Q3 results, advances promising oncology therapies

CytomX Therapeutics delivered solid financial performance in Q3 2024 with a focus on key oncology programs.
The company's Probody platform shows promise in addressing unmet medical needs in various cancers.
Challenges lie in optimizing dose escalation, enrollment, and expansion of therapies to maximize impact.
Strategic partnerships and disciplined capital allocation position CytomX for future growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P.

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year ago.

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

Lument Finance Trust

Quhuo Limited

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.

Buy Alert: 3 Penny Stocks That Will Explode in 2024

Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.

No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904.

Why Is CytomX (CTMX) Stock Down 43% Today?

CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.

CytomX stock down 30% despite encouraging cancer study results

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?

CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024.

Why Is CytomX (CTMX) Stock Up 180% Today?

- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD3, being assessed in a phase 1 trial. The company has a strategic collaboration with Amgen for CX-904 and with Astellas for CX-2051, an antibody-drug conjugate targeting EpCAM.

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025.

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -

News for CytomX Therapeutics Stock (CTMX)